GlassScriptPhysician profile
Haris Dzubur
NPI 1760725923
$25,962.18
in general payments reported to CMS, 2019-2025
37 companies · $2,425 in 2025
The $2,425 reported for 2025 was more than what 94% of Corneal and Contact Management providers received nationally (typical 2025 total: $227).
See the full distribution for Corneal and Contact Management
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $399 · 2020: $1,186 · 2021: $6,033 · 2022: $12K · 2023: $1,578 · 2024: $2,212 · 2025: $2,425.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,706 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $470 · Entertainment: $39.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,705.95 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $470.00 |
| Entertainment | $39.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $15,714.79 | 2019-2023 | Tobradex St, Flarex |
| Novartis Pharmaceuticals Corporation | $1,245.13 | 2019-2023 | |
| Mallinckrodt Hospital Products INC. | $988.81 | 2021-2025 | Acthar |
| Harrow Eye, LLC | $941.23 | 2024-2025 | Vevye |
| Bausch & Lomb Americas INC. | $925.38 | 2022-2025 | Infuse, Miebo, Xiidra |
| Tarsus Pharmaceuticals, INC. | $746.70 | 2024-2025 | Xdemvy |
| Dompe US, INC. | $681.62 | 2021-2025 | Oxervate |
| Coopervision INC. | $641.27 | 2021-2025 | Myday Contact Lens, Onefit Contact Lens, Misight Contact Lens |
| Alcon Vision LLC | $622.47 | 2019-2025 | Total30, Tryptyr, Rocklatan |
| Sun Pharmaceutical Industries INC. | $560.69 | 2020-2025 | Cequa |
| Biotissue Holdings INC. | $425.22 | 2019-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $388.92 | 2019-2021 | |
| Sight Sciences, INC. | $373.91 | 2019-2025 | Tearcare System, Omni Surgical System |
| Oyster Point Pharma, INC. | $339.02 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Rxsight INC | $266.83 | 2021-2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oasis Medical, INC. | $226.59 | 2019-2023 | Oasis Tears |
| Lkc Technologies, INC. | $183.78 | 2025 | |
| Abbvie INC. | $98.81 | 2022-2023 | Ozurdex |
| Topcon Healthcare, INC. | $97.67 | 2024 | |
| Optos, INC. | $52.85 | 2019-2023 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Johnson & Johnson Vision Care, INC. | $44.07 | 2020-2022 | |
| Glaukos Corporation | $42.02 | 2024 | Idose |
| Thea Pharma INC. | $38.58 | 2022-2023 | |
| Vyera Pharmaceuticals, LLC | $38.23 | 2021 | |
| Beaver-Visitec International, INC. | $37.71 | 2023 | |
| Vanda Pharmaceuticals INC. | $32.48 | 2020 | |
| Menicon America INC | $31.00 | 2019 | |
| Allergan, INC. | $25.33 | 2019-2021 | |
| Akorn Operating Company LLC | $21.19 | 2021 | |
| Santen INC. | $20.59 | 2023 | Verkazia |
| Akorn, INC. | $19.92 | 2020 | |
| Shire North American Group INC | $19.80 | 2019 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Tearlab Corp | $16.57 | 2019 | |
| Kala Pharmaceuticals, INC. | $15.01 | 2021 | |
| Synergeyes, INC. | $10.38 | 2022 | |
| Quidel Corporation | $10.37 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haris Dzubur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.